Omeprazole (PS) is a medicine containing the active ingredient(s) omeprazole. On this page you will find out more about Omeprazole (PS), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: omeprazole
Over 65 years of age?
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Information for medicine and pack size:
Omeprazole (PS) 20 mg enteric tablet, 5
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Omeprazole Tablets are indicated for: A. Gastro-Oesophageal Reflux Disease (GORD): 1. Symptomatic GORD: The relief of heartburn and other symptoms associated with GORD. 2. Erosive Oesophagitis: The treatment and prevention of relapse. B. Peptic Ulcers: 1. The treatment of duodenal and gastric ulcer. 2. Combination therapy for the treatment of peptic ulcer disease associated with Heliobacter pylori infection. 3. The treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. The prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. Long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be Heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. C. Zollinger-Ellison Syndrome: The treatment of Zollinger-Ellison Syndrome.
Table of characteristics
|Visual appearance||Red brown, oblong, enteric coated tablets.|
|Dosage Form||Tablet, enteric coated|
|Route of administration||Oral|
10 tablets: Prescription Only Medicine, or Prescription Animal Remedy
30 tablets: Prescription Only Medicine, or Prescription Animal Remedy
5 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||2 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.